PDF(Pubmed)
Abstract：
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a consequence of insulin resistance, insulin deficiency, or both. It is usually seen in adults and is a consequence of genetic (polygenic inheritance), endogenous (obesity and or hormonal factors), and environmental factors (e.g., obesogenic environment, endocrine disrupting chemicals, stress, and medicines). The prevalence of T2DM has increased over the past few decades. South Asians, including Indians, are more prone to central adiposity and develop lifestyle diseases like T2DM at body mass index values lower than those considered normal for the Western population. Generally, the first line of treatment is metformin monotherapy with lifestyle changes in patients with T2DM. Most of the research conducted on this drug is on Western subjects. Since the Indian population has genetic differences in the site of deposition of adipose and is more prone to develop lifestyle diseases, the effect of metformin may be different in Indians.
METHODS: Seventy-one (34 female, non-pregnant, non-lactating) adults with newly diagnosed T2DM were recruited in this short-duration pilot study after obtaining written informed consent. Patients regularly taking any drug were excluded, as were patients with chronic comorbidities. Treatment was initiated with metformin 500 mg OD. Lifestyle changes were recommended according to the age and physical condition of the patients. Anthropometric parameters (age, weight, height, BMI, waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR)), blood pressure, glycemic status (fasting and 2 h PP glucose and HbA1c), and lipid profile of the subjects were recorded before initiating and six months after initiating metformin monotherapy with lifestyle changes.
RESULTS: Small but statistically significant improvements were observed in the WHR,WHtR, blood pressure, blood glucose, and glycated hemoglobin. Although improvement was also observed in weight and lipid profile, these changes were not statistically significant.
CONCLUSIONS: This study shows that metformin monotherapy with lifestyle changes is suitable for patients of Indian origin and results in improvement in the WHR, WHtR, blood pressure, plasma glucose, and glycated hemoglobin.
METHODS: Seventy-one (34 female, non-pregnant, non-lactating) adults with newly diagnosed T2DM were recruited in this short-duration pilot study after obtaining written informed consent. Patients regularly taking any drug were excluded, as were patients with chronic comorbidities. Treatment was initiated with metformin 500 mg OD. Lifestyle changes were recommended according to the age and physical condition of the patients. Anthropometric parameters (age, weight, height, BMI, waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR)), blood pressure, glycemic status (fasting and 2 h PP glucose and HbA1c), and lipid profile of the subjects were recorded before initiating and six months after initiating metformin monotherapy with lifestyle changes.
RESULTS: Small but statistically significant improvements were observed in the WHR,WHtR, blood pressure, blood glucose, and glycated hemoglobin. Although improvement was also observed in weight and lipid profile, these changes were not statistically significant.
CONCLUSIONS: This study shows that metformin monotherapy with lifestyle changes is suitable for patients of Indian origin and results in improvement in the WHR, WHtR, blood pressure, plasma glucose, and glycated hemoglobin.
摘要：
背景：2型糖尿病（T2DM）是胰岛素抵抗的结果，胰岛素缺乏，或者两者兼而有之。它通常见于成人，是遗传（多基因遗传）的结果，内源性（肥胖和或激素因素），和环境因素(例如，肥胖环境，内分泌干扰物,压力，和药物）。在过去的几十年中，T2DM的患病率有所增加。南亚人,包括印第安人,在低于西方人群的体重指数值时，更容易发生中心性肥胖，并发展为生活方式疾病，如T2DM。一般来说,一线治疗是二甲双胍单药治疗2型糖尿病患者的生活方式改变.对这种药物进行的大多数研究都是针对西方主题。由于印度人口在脂肪沉积部位具有遗传差异，并且更容易患上生活方式疾病，二甲双胍的效果在印度人中可能不同。
方法：71（34名女性，没有怀孕,在获得书面知情同意书后,在这项短期试点研究中招募了非哺乳期)新诊断的2型糖尿病成人.定期服用任何药物的患者被排除在外，慢性合并症患者也是如此。用二甲双胍500mgOD开始治疗。根据患者的年龄和身体状况，建议改变生活方式。人体测量参数（年龄，体重,高度,BMI,腰臀比（WHR），和腰围高度比(WHtR))，血压,血糖状态（空腹和2小时PP葡萄糖和HbA1c），在开始二甲双胍单药治疗前和开始后6个月,随着生活方式的改变,记录受试者的血脂状况.
结果：在WHR中观察到微小但具有统计学意义的改善，WHtR,血压,血糖，和糖化血红蛋白.虽然在体重和血脂方面也观察到改善，这些变化没有统计学意义.
结论：这项研究表明，改变生活方式的二甲双胍单药治疗适用于印度裔患者，并可改善WHR，WHtR,血压,血浆葡萄糖，和糖化血红蛋白.
方法：71（34名女性，没有怀孕,在获得书面知情同意书后,在这项短期试点研究中招募了非哺乳期)新诊断的2型糖尿病成人.定期服用任何药物的患者被排除在外，慢性合并症患者也是如此。用二甲双胍500mgOD开始治疗。根据患者的年龄和身体状况，建议改变生活方式。人体测量参数（年龄，体重,高度,BMI,腰臀比（WHR），和腰围高度比(WHtR))，血压,血糖状态（空腹和2小时PP葡萄糖和HbA1c），在开始二甲双胍单药治疗前和开始后6个月,随着生活方式的改变,记录受试者的血脂状况.
结果：在WHR中观察到微小但具有统计学意义的改善，WHtR,血压,血糖，和糖化血红蛋白.虽然在体重和血脂方面也观察到改善，这些变化没有统计学意义.
结论：这项研究表明，改变生活方式的二甲双胍单药治疗适用于印度裔患者，并可改善WHR，WHtR,血压,血浆葡萄糖，和糖化血红蛋白.
